Selecta Biosciences Announces Appointment of Blaine Davis as Chief Financial Officer
WATERTOWN, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) — Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology…
Month: November 2022
Enlivex Receives Allocetra IND Clearance From The U.S. Food And Drug Administration For Treatment Of Patients with Advanced Solid Malignancies
IND filing followed encouraging preclinical studies conducted in collaboration with Yale Cancer Center that showed…
Ikena Oncology Announces New Program in Next-Generation MEK-RAF Inhibition and Provides Corporate Update
Novel best-in-class MEK-RAF complex inhibitor IK-595 targets RAS pathway; IND in 2023 Novel paralog-selective TEAD…
Crinetics Pharmaceuticals Provides Update on CRN04777 Program
SAN DIEGO, Nov. 28, 2022 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today provided…
VISIONARY-MS Trial Results Featured in Platform Presentation at PACTRIMS 2022: CNM-Au8® Demonstrated Global Neurological Improvement in Stable MS Patients as Adjunct to Background Disease Modifying Therapies
CNM-Au8 demonstrated low contrast vision improvement and global neurological improvement (low contrast vision, cognition, upper…
Cognition Therapeutics Highlights Phase 2 SHIMMER Study of CT1812 in Dementia with Lewy Bodies in Presentation at CTAD
Innovative trial addresses second most common dementia after Alzheimer’s disease, now enrolling patients at up…
Vaccinex Announces $3.8 Million Private Placement
ROCHESTER, N.Y., Nov. 28, 2022 (GLOBE NEWSWIRE) — Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology…
Lexicon Pharmaceuticals to Participate in the 34th Annual Piper Sandler Healthcare Conference and the 5th Annual Evercore ISI HealthCONx Conference
THE WOODLANDS, Texas, Nov. 28, 2022 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today…
Ocugen to Present at 3rd Annual Dry AMD Therapeutics Summit
MALVERN, Pa., Nov. 28, 2022 (GLOBE NEWSWIRE) — Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ:…
Zynerba Pharmaceuticals Announces Publication of Data from Phase 3 CONNECT-FX Study of Zygel™ in the Journal of Neurodevelopmental Disorders
Study finds patients with Fragile X who have a highly methylated FMR1 gene that were…
CinCor Pharma Announces Topline Data for Phase 2 HALO Trial Evaluating Selective Aldosterone Synthase Inhibitor Baxdrostat in Uncontrolled Hypertension
Primary endpoint in Intention to Treat (ITT) was not met despite large absolute reductions in…
Nabriva Therapeutics Announces Positive Topline Results from Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic Fibrosis
– PK Data and Safety Profile Consistent with Previous Studies in Healthy Subjects – –…
BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Israeli Ministry of Health
RESEARCH TRIANGLE PARK, N.C., Nov. 28, 2022 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today…
Emergex Generates Chikungunya Ligandome, a Milestone in the Development of its T cell Adaptive Vaccine
PRESS RELEASE Emergex Generates Chikungunya Ligandome, a Milestone in the Development of its T cell…
Oxitope Appoints Leading Interventional Cardiologist Gregg Stone to Advisory Board for Myocardial Reperfusion Injury
PRESS RELEASE Oxitope Appoints Leading Interventional Cardiologist Gregg Stone to Advisory Board for Myocardial Reperfusion…
Viridian Therapeutics To Participate In The Evercore ISI HealthCONx Conference
WALTHAM, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) — Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company…
Replay receives $1.5 million grant for its hypoimmunogenic technology platform
Replay receives $1.5 million grant for its hypoimmunogenic technology platform Replay developing uCell™, its universal,…
Athira Pharma to Present Preclinical Data Highlighting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND
HGF/MET small molecule positive modulator provides neuroprotection and improves motor and nerve function in a…
FibroGen to Participate at Bank of America 2022 Biotech SMID Cap Virtual Conference
SAN FRANCISCO, Nov. 28, 2022 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ: FGEN) today announced that…
XORTX Announces Completion of Screening and Enrollment in Bridging Pharmacokinetics Study
XRX-OXY-101 Study will inform the dose choice in the upcoming Phase 3 Clinical Trial CALGARY,…